Can Beta-2-Adrenergic Pathway Be a New Target to Combat SARS-CoV-2 Hyperinflammatory Syndrome?—Lessons Learned From Cancer
Antônio Barbieri, Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Palma(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nirmal Robinson(University of South Australia), Vincenzo Desiderio(University of Campania "Luigi Vanvitelli"), Nicola Maurea(Cancer Institute (WIA))
Cited by 40
Related Papers
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Basic principles of biobanking: from biological samples to precision medicine for patients
|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2021|223